ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2013
Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.Journal of translational medicine · 2023Article
- Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus.Cancer pathogenesis and therapy · 2023Review
- CD137Cancers · 2021Review
- The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer.Cancers · 2020Review
- Immunotherapy with Monoclonal Antibodies in Lung Cancer of Mice: Oxidative Stress and Other Biological Events.Cancers · 2019Article
- Checkpoint inhibitors in ovarian cancer: A review of preclinical data.Gynecologic oncology reports · 2019Review
- An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.International journal of molecular sciences · 2019Review
- Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.Clinical and experimental immunology · 2019Review
- A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8Cancer immunology research · 2019Article
- Tumor Regression and Cure Depends on Sustained Th1 Responses.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018Article
- Immune checkpoint inhibitors in cancer therapy.Journal of biomedical research · 2018Article
- Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression.Cancers · 2018Article
- Armed oncolytic viruses: A kick-start for anti-tumor immunity.Cytokine & growth factor reviews · 2018Review
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Journal of gynecologic oncology · 2017Review
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.Frontiers in oncology · 2016Review
- Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations.Cancers of the head & neck · 2016Review
- IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Immunomodulatory antibody therapy of cancer: the closer, the better.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.Journal of translational medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Mice with intraperitoneal ID8 ovarian carcinoma or subcutaneous SW1 melanoma were injected with monoclonal antibodies (mAbs) to CD137PD-1CTLA4 7-15 days after tumor initiation. Survival of mice with ID8 tumors tripled and >40% of mice with SW1 tumors remained healthy >150 days after last treatment and are probably cured. Therapeutic efficacy was associated with a systemic immune response with memory and antigen specificity, required CD4 cells and involved CD8 cells and NK cells to a less extent. The 3 mAb combination significantly decreased CD19 cells at tumor sites, increased IFN-γ and TNF-α producing CD4 and CD8 T cells and mature CD86 dendritic cells (DC), and it increased the ratios of effector CD4 and CD8 T cells to CD4Foxp3 regulatory T (Treg) cells and to CD11bGr-1 myeloid suppressor cells (MDSC). This is consistent with shifting the tumor microenvironment from an immunosuppressive Th2 to an immunostimulatory Th1 type and is further supported by PCR data. Adding an anti-CD19 mAb to the 3 mAb combination in the SW1 model further increased therapeutic efficacy. Data from ongoing experiments show that intratumoral injection of a combination of mAbs to CD137PD-1CTLA4CD19 can induce complete regression and dramatically prolong survival also in the TC1 carcinoma and B16 melanoma models, suggesting that the approach has general validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.